EconPapers    
Economics at your fingertips  
 

Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

Pingyu Chen, Mengjie Luo, Yanqiu Chen, Yanlei Zhang, Chao Wang and Hongchao Li ()
Additional contact information
Pingyu Chen: China Pharmaceutical University
Mengjie Luo: China Pharmaceutical University
Yanqiu Chen: China Pharmaceutical University
Yanlei Zhang: State Key Laboratory of Neurology and Oncology Drug Development (Jiangsu Simcere Pharmaceutical Co.,Ltd., Jiangsu Simcere Diagnostics Co.,Ltd.)
Chao Wang: State Key Laboratory of Neurology and Oncology Drug Development (Jiangsu Simcere Pharmaceutical Co.,Ltd., Jiangsu Simcere Diagnostics Co.,Ltd.)
Hongchao Li: China Pharmaceutical University

Health Economics Review, 2024, vol. 14, issue 1, 1-10

Abstract: Abstract Background Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogenase from China’s healthcare system perspective. Methods A combination of the decision tree and Markov model was constructed to evaluate the cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase in the treatment of acute ischemic stroke over a lifetime horizon. Efficacy data were derived from pivotal clinical trials of edaravone dexborneol and human urinary kallidinogenase (TASTE trial and RESK trial, respectively) and adjusted using matching-adjusted indirect comparison. Cost and health utility inputs were extracted from published literature and open databases. One-way deterministic sensitivity and probabilistic sensitivity analyses were performed to examine the robustness of the results. Results Compared with human urinary kallidinogenase, edaravone dexborneol generated 0.153 incremental quality-adjusted life years (QALYs) with an incremental cost of ¥856, yielding an incremental cost-effectiveness ratio of ¥5,608 per QALY gained under the willingness-to-pay threshold (one-time gross domestic product per capita). Both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis demonstrated the robustness of the base case results. Conclusions Edaravone dexborneol is a cost-effective treatment choice for acute ischemic stroke patients compared with human urinary kallidinogenase in China.

Keywords: Cost Effectiveness; Edaravone dexborneol; Human urinary kallidinogenase; Acute ischemic stroke; Matching adjusted indirect comparison (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-024-00479-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00479-6

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-024-00479-6

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-04-12
Handle: RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00479-6